Table 1:
Studies Investigating Different Substrate Ablation Strategies for VT (continued)
| Ablation Method | Study | Mapping Catheter | Voltage Map Cutoff | Procedure Time | Ablation Catheter | RF Time or No. of Lesions |
|---|---|---|---|---|---|---|
| Linear ablation | Marchlinski et al. 200010 | Ab cath | 0.5–1.5 mV | 9.4 hours | Nonirrigated | 59 ± 34 lesions |
| Soejima et al. 200172 | Ab cath | 0.5–1.5 mV | 7.4 hours | Nonirrigated/open irrigated/closed irrigated | 21 ± 10 lesions | |
| LP ablation | Volkmer et al. 200616 | Ab cath | 0.5–1.5 mV | 3.9 ± 1.1 hours | Noirrigated | 11 ± 8 lesions |
| Arenal et al. 200373 | Ab cath | 0.5–1.5 mV | 7.9 ± 2.1 hours | Nonirrigated/open irrigated | 14 ± 6 lesions | |
| Nogami et al. 200874 | Ab cath | 0.1–1.5 mV | 3.6 ± 1.1 hours | Nonirrigated | 17 ± 10 lesions | |
| Garcia et al. 200975 | Ab cath | 0.5–1.5 mV (endo)/ 0.5–1.0 mV (epi) | N/A | Nonirrigated/open irrigated | 35 ± 26 lesions (endo)/ 37 ± 21 lesions (epi) | |
| Bai et al. 201176 | Ab cath | 0.5–1.5 mV (endo)/ 0.5–1.5 mV (epi) | 5.3 ± 1.2 hours | Open irrigated | 26 ± 14 minutes | |
| Vergara et al. 201277 | Ab cath/Livewire™/AFocus™ II | 0.5–1.5 mV (endo)/ 0.5–1.0 mV (epi) | NA | Open irrigated | N/A | |
| Arenal et al. 201378 | Ab cath | 0.1–1.5 mV | 2.9 ± 0.8 hours | Open irrigated | 11 ± 5 minutes | |
| LAVA | Jaïs et al. 201219 | Ab cath/PentaRay® | 0.5–1.5 mV (endo)/ 0.5–1.0 mV (epi) | 2.5 ± 1.2 hours | Open irrigated | 23 ± 11 minutes |
| Wolf et al. 201820 | Multielectrode catheter in 89 patients/Ab cath in 70 patients | 0.5–1.5 mV (endo)/ 0.5–1.0 mV (epi); 0.2–0.8 mV was used in 6 patients with Rhythmia™ | 4.1 ± 1.3 hours | Open irrigated | 36 ± 20 minutes | |
| Scar homogenization | Di Biase et al. 201511 | Ab cath | 0.5–1.5 mV (endo)/ 0.5–1.5 mV (epi) | 4.2 ± 1.3 hours | Open irrigated | 68 ± 21 minutes |
| Di Biase et al. 201217 | Ab cath | 0.5–1.5 mV (endo)/ 0.5–1.5 mV (epi) | 4.8 ± 1.5 hours | Open irrigated | 74 ± 21 minutes | |
| Scar dechanneling | Berruezo et al. 201238 | Ab cath | 0.5–1.5 mV (endo)/ 0.5–1.5mV (epi) | 3.0 ± 1.0 hours | Open irrigated | 6.3 (4–8.7) lesions |
| Tung et al. 201381 | DecaNav® in 3 patients/Livewire™ in 16 patients/Constellation™ in 2 patients | 0.5–1.5 mV (endo)/ 0.5–1.5 mV (epi) | N/A | Open irrigated (including Thermocool® SF)/closed irrigated | 7 (4–14) lesions | |
| Berruezo et al. 201582 | NA | 0.5–1.5 mV (endo)/ 0.5–1.5 mV (epi) | 3.8 ± 1.1 hours | Open irrigated | 28 ± 16 minutes | |
| Fernández-Armenta et al. 2016102 | Ab cath | 0.5–1.5 mV (endo)/ 0.5–1.5 mV (epi) | 3.5 ± 1.1 hours | Open irrigated | 23 ± 14 minutes | |
| Core isolation | Tzou et al. 201579 | Ab cath | 0.5–1.5 mV (endo)/ 0.5–1.0 mV (epi) | 5.4 ± 2.0 hours | Open irrigated (including Thermocool® SF) | 111 ± 91 lesions |
| MRI-based scar dechanneling | Andreu et al. 201783 | Ab cath | 0.5–1.5 mV (endo)/ 0.5–1.5 mV (epi) | 3.8 ± 1.1 hours | Open irrigated | 19 ± 12 minutes |
Ab cath: ablation catheter; LAVA: local abnormal ventricular activity; LP: late potential; MRI: magnetic resonance imaging; No.: number; RF: radiofrequency. Livewire™ and AFocus™ II are the property of Abbott Laboratories, Chicago, IL, USA. DecaNav®, PentaRay®, and Thermocool® SF are the property of Biosense Webster, Diamond Bar, CA, USA. Constellation™ is the property of Boston Scientific, Natick, MA, USA.